Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) announced on Wednesday that it has received approval from Japan's Ministry of Health, Labour and Welfare for Nucala (mepolizumab) to treat chronic rhinosinusitis with nasal polyps (CRSwNP) in adults who are inadequately controlled with standard treatments. Nucala is the first biologic in Japan to offer a four-week dosing schedule for this condition.
CRSwNP affects 1% to 4% of the population, with 40% of cases remaining uncontrolled. The condition is characterised by nasal obstruction, loss of smell, and other symptoms that significantly impact patients' quality of life. While surgery can remove nasal polyps, they often regrow due to underlying inflammation.
Approval of Nucala is based on positive results from the phase III MERIT trial, which demonstrated significant improvements in nasal obstruction and patient quality of life. This marks the third indication for Nucala in Japan for an IL-5 mediated condition, following approvals for asthma and eosinophilic granulomatosis with polyangiitis.
GSK continues to expand its respiratory portfolio, focusing on innovative treatments for a range of respiratory diseases.
Biosergen completes first successful BSG005 treatment in invasive fungal trial
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
EydisBio receives USD2.6m SBIR grant from NIH's National Heart, Lung, and Blood Institute
Hyundai Bioscience to conduct Phase 3 trial for high-risk COVID-19 patients
GSK's Nucala approved in Japan for chronic rhinosinusitis with nasal polyps
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
Getinge to acquire Paragonix Technologies
Bridge Biotherapeutics and HitGen sign joint research agreement
Johnson & Johnson receives FDA approval for lung cancer treatment
GSK secures Breakthrough Therapy Designation for lung cancer drug
Phanes Therapeutics' PT217 receives US FDA orphan drug designation
Akeso's ivonescimab supplemental New Drug Application receives Chinese regulator's priority review
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults